Phase 1/2 Study of the Safety and Response of P-BCMA-101 CAR-T Cells in Patients with Relapsed/Refractory (r/r) Multiple Myeloma (MM) (PRIME) with Novel Therapeutic Strategies

Caitlin L. Costello; Adam D. Cohen; Krina K. Patel; Syed S Ali; Jesus G. Berdeja; Nina Shah; Siddhartha Ganguly; Mehmet Hakan Kocoglu; Mehrdad Abedi; Eric M. Ostertag; Chris E Martin; Majid Ghoddussi; Devon J Shedlock; Joanne McCaigue; Hamid Namini; Sreeni Yalamanchili; Matthew A. Spear; Tara K. Gregory

doi:10.1182/BLOOD-2020-142695

Phase 1/2 Study of the Safety and Response of P-BCMA-101 CAR-T Cells in Patients with Relapsed/Refractory (r/r) Multiple Myeloma (MM) (PRIME) with Novel Therapeutic Strategies

Caitlin L. Costello
, Adam D. Cohen
, Krina K. Patel
, Syed S Ali
, Jesus G. Berdeja
, Nina Shah
, Siddhartha Ganguly
, Mehmet Hakan Kocoglu
, Mehrdad Abedi
, Eric M. Ostertag
, Chris E Martin
, Majid Ghoddussi
, Devon J Shedlock
, Joanne McCaigue
, Hamid Namini
, Sreeni Yalamanchili
, Matthew A. Spear
, Tara K. Gregory

University of California, San Diego
University of Pennsylvania
University of Texas MD Anderson Cancer Center
Johns Hopkins University
Sarah Cannon Research Institute
University of California, San Francisco
University of Kansas
University of Maryland, College Park
University of California, Davis
Poseida Therapeutics, Inc., San Diego, CA
Poseida Therapeutics, San Diego, CA

Research output: Contribution to journal › Article › peer-review

Original language	American English
Journal	Blood
Volume	136
DOIs	https://doi.org/10.1182/BLOOD-2020-142695
State	Published - Nov 5 2020
Externally published	Yes

Disciplines

Medicine and Health Sciences
Family Medicine

Access to Document

10.1182/BLOOD-2020-142695License: Unspecified

Cite this

Costello, C. L., Cohen, A. D., Patel, K. K., Ali, S. S., Berdeja, J. G., Shah, N., Ganguly, S., Kocoglu, M. H., Abedi, M., Ostertag, E. M., Martin, C. E., Ghoddussi, M., Shedlock, D. J., McCaigue, J., Namini, H., Yalamanchili, S., Spear, M. A., & Gregory, T. K. (2020). Phase 1/2 Study of the Safety and Response of P-BCMA-101 CAR-T Cells in Patients with Relapsed/Refractory (r/r) Multiple Myeloma (MM) (PRIME) with Novel Therapeutic Strategies. Blood, 136. https://doi.org/10.1182/BLOOD-2020-142695

Costello, CL, Cohen, AD, Patel, KK, Ali, SS, Berdeja, JG, Shah, N, Ganguly, S, Kocoglu, MH, Abedi, M, Ostertag, EM, Martin, CE, Ghoddussi, M, Shedlock, DJ, McCaigue, J, Namini, H, Yalamanchili, S, Spear, MA & Gregory, TK 2020, 'Phase 1/2 Study of the Safety and Response of P-BCMA-101 CAR-T Cells in Patients with Relapsed/Refractory (r/r) Multiple Myeloma (MM) (PRIME) with Novel Therapeutic Strategies', Blood, vol. 136. https://doi.org/10.1182/BLOOD-2020-142695

@article{5b767d20a962413ebf97cbd12617764e,

title = "Phase 1/2 Study of the Safety and Response of P-BCMA-101 CAR-T Cells in Patients with Relapsed/Refractory (r/r) Multiple Myeloma (MM) (PRIME) with Novel Therapeutic Strategies",

author = "Costello, \{Caitlin L.\} and Cohen, \{Adam D.\} and Patel, \{Krina K.\} and Ali, \{Syed S\} and Berdeja, \{Jesus G.\} and Nina Shah and Siddhartha Ganguly and Kocoglu, \{Mehmet Hakan\} and Mehrdad Abedi and Ostertag, \{Eric M.\} and Martin, \{Chris E\} and Majid Ghoddussi and Shedlock, \{Devon J\} and Joanne McCaigue and Hamid Namini and Sreeni Yalamanchili and Spear, \{Matthew A.\} and Gregory, \{Tara K.\}",

note = "Oral and Poster Abstracts Oral 653. Myeloma/Amyloidosis: Therapy, excluding Transplantation: CAR T Therapies for Myeloma: Novel Approaches and Longer-Term Follow Up Data Biological, Therapies, CAR-Ts Caitlin L. Costello, MD 1, Adam D. Cohen, MD 2, Krina K. Patel, M.D. 3, Syed S Ali, MD 4, Jesus G.",

year = "2020",

month = nov,

day = "5",

doi = "10.1182/BLOOD-2020-142695",

language = "American English",

volume = "136",

journal = "Blood",

publisher = "American Society of Hematology",

}

TY - JOUR

T1 - Phase 1/2 Study of the Safety and Response of P-BCMA-101 CAR-T Cells in Patients with Relapsed/Refractory (r/r) Multiple Myeloma (MM) (PRIME) with Novel Therapeutic Strategies

AU - Costello, Caitlin L.

AU - Cohen, Adam D.

AU - Patel, Krina K.

AU - Ali, Syed S

AU - Berdeja, Jesus G.

AU - Shah, Nina

AU - Ganguly, Siddhartha

AU - Kocoglu, Mehmet Hakan

AU - Abedi, Mehrdad

AU - Ostertag, Eric M.

AU - Martin, Chris E

AU - Ghoddussi, Majid

AU - Shedlock, Devon J

AU - McCaigue, Joanne

AU - Namini, Hamid

AU - Yalamanchili, Sreeni

AU - Spear, Matthew A.

AU - Gregory, Tara K.

N1 - Oral and Poster Abstracts Oral 653. Myeloma/Amyloidosis: Therapy, excluding Transplantation: CAR T Therapies for Myeloma: Novel Approaches and Longer-Term Follow Up Data Biological, Therapies, CAR-Ts Caitlin L. Costello, MD 1, Adam D. Cohen, MD 2, Krina K. Patel, M.D. 3, Syed S Ali, MD 4, Jesus G.

PY - 2020/11/5

Y1 - 2020/11/5

UR - https://ash.confex.com/ash/2020/webprogram/Paper142695.html

U2 - 10.1182/BLOOD-2020-142695

DO - 10.1182/BLOOD-2020-142695

M3 - Article

VL - 136

JO - Blood

JF - Blood

ER -

Phase 1/2 Study of the Safety and Response of P-BCMA-101 CAR-T Cells in Patients with Relapsed/Refractory (r/r) Multiple Myeloma (MM) (PRIME) with Novel Therapeutic Strategies

Disciplines

Access to Document

Other files and links

Cite this